This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2016 May;68(5):1049-52.

doi: 10.1002/art.39568.

Editorial: Biosimilars: New or Déjà Vu?

Affiliations

PMID: 26748580
DOI: 10.1002/art.39568

Editorial

Editorial: Biosimilars: New or Déjà Vu?

Jonathan Kay. Arthritis Rheumatol. 2016 May.

. 2016 May;68(5):1049-52.

doi: 10.1002/art.39568.

Author

Affiliation

¹ UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester.

PMID: 26748580
DOI: 10.1002/art.39568

No abstract available

PubMed Disclaimer

Comment on

Brief Report: Utilization of the First Biosimilar Infliximab Since Its Approval in South Korea.
Kim SC, Choi NK, Lee J, Kwon KE, Eddings W, Sung YK, Ji Song H, Kesselheim AS, Solomon DH. Kim SC, et al. Arthritis Rheumatol. 2016 May;68(5):1076-9. doi: 10.1002/art.39546. Arthritis Rheumatol. 2016. PMID: 26662931 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Other Literature Sources
- scite Smart Citations